Chronic hypercortisolism causes more persistent visceral adiposity than HFD-induced obesity.
Excessive and prolonged glucocorticoid (GC) exposure, resulting from either prescribed or endogenous hypercortisolism, is associated with a high cardiovascular and metabolic burden (Cushing's syndrome). Although previous studies in humans and mice have reported heterogeneous data about the persistence of metabolic syndrome features after remission of hypercortisolism, there is still controversy as to whether this is due to the deleterious changes induced by GCs during active disease or the result of various other factors interfering in the recovery period. In order to study metabolic effects after remission, we used a reversible mouse model of corticosterone (CORT) (100 µg/ml) administration in drinking water for five weeks, followed by a 10-week recovery period. We compared CORT-induced effects at these time points with a high-fat diet-treated group (HFD 45%) and a vehicle group (VEH). Plasma CORT, 11β-HSD activity, food intake, glucose levels, interscapular brown adiposity, hepatic triglycerides and muscle mass were found altered during CORT treatment but normalized after recovery. Although hyperinsulinemia and insulin resistance were increased during CORT and HFD treatment, insulin homeostasis remained altered following the recovery period only in CORT-treated mice. Subcutaneous and visceral adipose tissues (SAT and VAT) were enlarged during HFD and CORT treatment as measured by MRI. However, increased muscle lipid content, adiposity and macrophage infiltration in VAT were only present in the CORT group following recovery. Taken together, CORT-induced insulin alterations were more potent than HFD-induced ones during the same period of treatment, and also more persistent long term . Moreover, we demonstrated that CORT treatment induces more long-lasting visceral adipose tissue enlargement than HFD.
G Garcia-Eguren, Group of Endocrine Disorders, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain.,
O Giró, Group of Encocrine Disorders, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain.,
M Romero, Biochemistry and Molecular Medicine, Universitat de Barcelona Facultat de Biologia, Barcelona, Spain.,
M Grasa, Biochemistry and Molecular Medicine, Universitat de Barcelona Facultat de Biologia, Barcelona, Spain.
F Hanzu, Endocrinology and Nutrition, Hospital Clinic de Barcelona, Barcelona, Spain.
Pub Type(s)Journal Article